

will thereafter be continuously published in the Chart Supplement.

\* \* \* \* \*

Paragraph 6002 Class E Airspace Areas Designated as Surface Areas.

\* \* \* \* \*

**ASW TX E2 Beaumont/Port Arthur, TX [Amended]**

Jack Brooks Regional Airport, TX (Lat. 29°57'03" N, long. 94°01'15" W) Within a 5-mile radius of Jack Brooks Regional Airport. This Class E airspace area is effective during the specific dates and times established in advance by a Notice to Air Missions. The effective dates and times will thereafter be continuously published in the Chart Supplement.

\* \* \* \* \*

Paragraph 6005 Class E Airspace Areas Extending Upward From 700 Feet or More Above the Surface of the Earth.

\* \* \* \* \*

**ASW TX E5 Beaumont/Port Arthur, TX [Amended]**

Jack Brooks Regional Airport, TX (Lat. 29°57'03" N, long. 94°01'15" W) Beaumont Municipal Airport, TX (Lat. 30°04'13" N, long. 94°12'54" W) Orange County Airport, TX (Lat. 30°04'06" N, long. 93°48'14" W) That airspace extending upward from 700 feet above the surface within a 7.5-mile radius of Jack Brooks Regional Airport; and within a 6.4-mile radius of Beaumont Municipal Airport; and within a 6.5-mile radius of Orange County Airport.

\* \* \* \* \*

Issued in Fort Worth, Texas, on May 1, 2024.

**Steven T. Phillips,**  
Acting Manager, Operations Support Group,  
ATO Central Service Center.

[FR Doc. 2024-09872 Filed 5-14-24; 8:45 am]

**BILLING CODE 4910-13-P**

**DEPARTMENT OF COMMERCE  
International Trade Administration**

**15 CFR Part 326**  
[Docket No. 240226-0059]  
RIN 0625-AB24

**The U.S. and Foreign Commercial Service Pilot Fellowship Program; Correction**

**AGENCY:** International Trade Administration, Department of Commerce.

**ACTION:** Final rule; correction.

**SUMMARY:** The International Trade Administration is correcting a final rule published in the **Federal Register** on May 7, 2024, regarding The U.S. and Foreign Commercial Service Pilot Fellowship Program. This correction applies to the effective date of final rule.

**DATES:** Effective May 15, 2024.

**FOR FURTHER INFORMATION CONTACT:** Wendy Thompson at [wendy.thompson@trade.gov](mailto:wendy.thompson@trade.gov) or 202-754-4075.

**SUPPLEMENTARY INFORMATION:** In FR Doc. 2024-09863, on page 37972 in the **Federal Register** of Tuesday, May 7, 2024, in the second column, correct the **DATES** caption by adding “, 2024” after “May 6”.

Dated: May 8, 2024  
**Kimberly White-Bacon,**  
Program Manager.  
[FR Doc. 2024-10561 Filed 5-14-24; 8:45 am]  
**BILLING CODE 3510-FP-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Parts 510, 520, 522, 524, 529, and 558**  
[Docket No. FDA-2024-N-0002]

**New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Applications, Change of Sponsor, Change of Sponsor Address**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule; technical amendments.

**SUMMARY:** The Food and Drug Administration (FDA or we) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during January, February, and March 2024. The animal drug regulations are also being amended to improve their accuracy and readability.

**DATES:** This rule is effective May 15, 2024.

**FOR FURTHER INFORMATION CONTACT:** George K. Haibel, Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402-5689, [George.Haibel@fda.hhs.gov](mailto:George.Haibel@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:**

**I. Approvals**

FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during January, February, and March 2024, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOIA Summaries) under the Freedom of Information Act (FOIA). These documents, along with marketing exclusivity and patent information, may be obtained at *Animal Drugs @FDA*: <https://animaldrugsatfda.fda.gov/adafda/views/#/search>.

TABLE 1—ORIGINAL AND SUPPLEMENTAL NADAs AND ANADAs APPROVED DURING JANUARY, FEBRUARY, AND MARCH 2024 REQUIRING EVIDENCE OF SAFETY AND/OR EFFECTIVENESS

Date of approval	File No.	Sponsor (drug labeler code)	Product name	Effect of the action	21 CFR section
January 11, 2024 .....	200-766	Aurora Pharmaceutical, Inc., 1196 Highway 3 South, Northfield, MN 55057-3009 (051072).	EQUICOXIB (firocoxib) Oral Solution.	Original approval as a generic copy of NADA 141-253.	520.929